ASM 8
Alternative Names: ASM8; TPI-ASM8Latest Information Update: 13 Dec 2023
Price :
$50 *
At a glance
- Originator Topigen Pharmaceuticals
- Developer Syntara Limited
- Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides
- Mechanism of Action CCR3 receptor antagonists; Granulocyte macrophage colony stimulating factor antagonists; Interleukin 3 receptor antagonists; Interleukin 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic asthma; Asthma